{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:44:04Z","timestamp":1761749044276,"version":"build-2065373602"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,29]]},"DOI":"10.7759\/cureus.95668","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:18:38Z","timestamp":1761747518000},"source":"Crossref","is-referenced-by-count":0,"title":["Maintenance Low-Dose BRAF Inhibition and Rituximab in Relapsed Hairy Cell Leukemia: A Therapeutic Alternative"],"prefix":"10.7759","author":[{"given":"Anshul","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"Koilpillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Baidas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras LR","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016, 66:443-59. 10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.2.349.349","article-title":"Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement","volume":"61","author":"Golomb HM","year":"1983","unstructured":"Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood. 1983, 61:349-52. 10.1182\/blood.V61.2.349.349","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.3.817.817","article-title":"Treatment of hairy cell leukemia with recombinant -interferon: quantitative study of bone marrow changes during the first months of treatment","volume":"67","author":"Flandrin G","unstructured":"Flandrin G, Sigauz F, Castaigne S, et al.. Treatment of hairy cell leukemia with recombinant -interferon: quantitative study of bone marrow changes during the first months of treatment. Blood. 67:817-20. 10.1182\/blood.V67.3.817.817","journal-title":"Blood"},{"key":"ref4","article-title":"Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986","volume":"1","author":"Spielberger RT","year":"1994","unstructured":"Spielberger RT, Mick R, Ratain MJ, Golomb HM. Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leukemia Lymphoma. 1994, 1:89-93.","journal-title":"Leukemia Lymphoma"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.6.448","article-title":"Pentostatin in hairy cell leukemia: treatment by the special exception mechanism","volume":"81","author":"Grem JL","year":"1989","unstructured":"Grem JL, King SA, Cheson BD, Leyland-Jones B, Wittes RE. Pentostatin in hairy cell leukemia: treatment by the special exception mechanism. J Natl Cancer Inst. 1989, 81:448-53. 10.1093\/jnci\/81.6.448","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704023161401","article-title":"Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin)","volume":"316","author":"Spiers AS","year":"1987","unstructured":"Spiers AS, Moore D, Cassileth PA, et al.. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med. 1987, 316:825-30. 10.1056\/NEJM198704023161401","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1995.0016","article-title":"Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine","volume":"21","author":"Konwalinka G","year":"1995","unstructured":"Konwalinka G, Schirmer M, Hilbe W, et al.. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood Cells Mol Dis. 1995, 21:142-51. 10.1006\/bcmd.1995.0016","journal-title":"Blood Cells Mol Dis"},{"key":"ref8","article-title":"Bone marrow biopsy in hairy cell leukemia (HCL) patients. Histological and immunohistological analysis of 46 cases treated with different therapies","volume":"14","author":"Pileri S","year":"1994","unstructured":"Pileri S, Sabattini E, Poggi S, et al.. Bone marrow biopsy in hairy cell leukemia (HCL) patients. Histological and immunohistological analysis of 46 cases treated with different therapies. Leukemia Lymphoma. 1994, 14:67-71.","journal-title":"Leukemia Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0014","article-title":"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia","volume":"102","author":"Nieva J","year":"2003","unstructured":"Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003, 102:810-3. 10.1182\/blood-2003-01-0014","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.4910.4910","article-title":"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma","volume":"116","author":"Spurgeon S","year":"2010","unstructured":"Spurgeon S, Pindyck T, Loriaux MM, et al.. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Blood. 2010, 116:4910.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman RJ","year":"2018","unstructured":"Kreitman RJ, Dearden C, Zinzani PL, et al.. Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia. Leukemia. 2018, 32:1768-77. 10.1038\/s41375-018-0210-1","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci E","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, et al.. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011, 364:2305-15. 10.1056\/NEJMoa1014209","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030697","article-title":"The genomics of hairy cell leukaemia and splenic diffuse red pulp lymphoma","volume":"14","author":"Oscier D","year":"2022","unstructured":"Oscier D, Stamatopoulos K, Mirandari A, Strefford J. The genomics of hairy cell leukaemia and splenic diffuse red pulp lymphoma. Cancers (Basel). 2022, 14:10.3390\/cancers14030697","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci E","year":"2015","unstructured":"Tiacci E, Park JH, De Carolis L, et al.. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015, 373:1733-47. 10.1056\/NEJMoa1506583","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680074. Epub 2016 Mar 3.","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"9","author":"Dietrich S","year":"2016","unstructured":"Dietrich S, Pircher A, Endris V, et al.. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood. 2016, 9:2847-55. 10.1182\/blood-2015-11-680074. Epub 2016 Mar 3.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0646-y","article-title":"BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials","volume":"34","author":"Liebers N","year":"2020","unstructured":"Liebers N, Roider T, Bohn JP, et al.. BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. Leukemia. 2020, 34:1454-7. 10.1038\/s41375-019-0646-y","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci E","year":"2021","unstructured":"Tiacci E, De Carolis L, Simonetti E, et al.. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021, 384:1810-23. 10.1056\/NEJMoa2031298","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124478","article-title":"First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL","volume":"134","author":"Park JH","year":"2019","unstructured":"Park JH, Shukla M, Salcedo JM, et al.. First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL. Blood. 2019, 134:3998. 10.1182\/blood-2019-124478","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404344-maintenance-low-dose-braf-inhibition-and-rituximab-in-relapsed-hairy-cell-leukemia-a-therapeutic-alternative","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:18:39Z","timestamp":1761747519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404344-maintenance-low-dose-braf-inhibition-and-rituximab-in-relapsed-hairy-cell-leukemia-a-therapeutic-alternative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.95668","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}